form
powder
feed ratio
lactide:glycolide 80:20
mol wt
PEG average Mn 5,000, PLGA Mn 5,000
impurities
≤5000 ppm (GC)
shipped in
dry ice
storage temp.
−20°C
正在寻找类似产品? 访问 产品对比指南
General description
Contains ≤500 ppm impurities by GC, including trace monomer and residual organics.
Application
Biocompatible block copolymer. Can be used in the formation of nanoparticles for drug delivery. Potential use in the targeted and/or controlled release of cancer drugs, anti-inflammatory drugs, antibiotics, or anesthetic agents.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug.
Miller MA, et al.
Nature Communications, 6 (2015)
Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation.
Danhier F, et al.
J. Controlled Release, 133, 11-17 (2009)
Yihan Xu et al.
Journal of biomedical materials research. Part B, Applied biomaterials, 105(6), 1692-1716 (2016-04-22)
Poly (lactic-co-glycolic acid) (PLGA) copolymers have been broadly used in controlled drug release applications. Because these polymers are biodegradable, they provide an attractive option for drug delivery vehicles. There are a variety of material, processing, and physiological factors that impact
R Gref et al.
Science (New York, N.Y.), 263(5153), 1600-1603 (1994-03-18)
Injectable nanoparticulate carriers have important potential applications such as site-specific drug delivery or medical imaging. Conventional carriers, however, cannot generally be used because they are eliminated by the reticulo-endothelial system within seconds or minutes after intravenous injection. To address these
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持